Tissue Regenix Group PLC Hardman & Co: Full-year 2017 - what to look for
March 08 2018 - 2:15AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
08 March 2018
Hardman & Co: Full-year 2017 - what to look for
Full-year 2017: what to look for - TRX has a broad portfolio of
regenerative medicine products developed from decellularised human
and porcine soft tissues for the wound care, orthopaedics, and
cardiac markets. Since the launch of DermaPure, focus has been on
expanding in the US wound care and orthopaedic markets: in August
2017, TRX acquired CellRight Technologies, providing synergistic
bone regeneration technology. Full-year 2017 results will be the
first to reflect the acquisition and will include five months of
the enlarged entity. Sales from all three business segments are
forecast to be strong (total GBP5.15m). We set out our underlying
growth expectations below.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/08.03.18-full-year-2017-what-to-look-for.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea
EC2M 1NH Hill
www.hardmanandco.com Dr Gregoire
Follow us on Twitter Pave
@HardmanandCo
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGGFNNGGRZM
(END) Dow Jones Newswires
March 08, 2018 02:15 ET (07:15 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024